SUBSCRIBE
SUBSCRIBE
News   Policy

Schering-Plough Corporation Anesthesia Drug Gets Mixed FDA Review

March 10, 2008 | 
1 min read
WASHINGTON (Reuters) - A Schering-Plow Corp drug to reverse the effects of anesthesia appears to be generally safe, U.S. regulatory staff said, but they questioned how the company defined effectiveness in a key study.
Regulatory
Food and Drug Administration (FDA) Organon
MORE ON THIS TOPIC
The white plane flies against the blue sky, leaving a white trail. Vector illustration
Vaccines
Postponed ACIP Meeting Rescheduled for Mid-March
February 25, 2026
 · 
3 min read
 · 
Tristan Manalac
Alarm clock with pause sign, take a break, menopause concept, hormone replacement therapy
Regulatory
Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study
February 25, 2026
 · 
2 min read
 · 
Tristan Manalac
Podcast
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
February 25, 2026
 · 
2 min read
 · 
Heather McKenzie
Capitol Hill COVID-19 blood testing, abstract virus testing during pandemic concept, State Building Washington DC, USA, 3d illustration
FDA
Opinion: Balancing Safety Access in Rare Disease—Lessons From Sarepta
February 25, 2026
 · 
6 min read
 · 
Joshua R. Mansbach